Pigmentation PAX‐ways: the role of Pax3 in melanogenesis, melanocyte stem cell maintenance, and disease

Transcription factors initiate programs of gene expression and are catalysts in downstream molecular cascades that modulate a variety of cellular processes. Pax3 is a transcription factor that is important in the melanocyte and influences melanocytic proliferation, resistance to apoptosis, migration, lineage specificity and differentiation. In this review, we focus on Pax3 and the molecular pathways that Pax3 is a part of during melanogenesis and in the melanocyte stem cell. These roles of Pax3 are emphasized during the development of diseases and syndromes resulting from either too much or too little Pax3 function. Due to its key task in melanocyte stem cells and tumors, the Pax3 pathway may provide an ideal target for either stem cell or cancer therapies.

[1]  A. Hollenbach,et al.  Identification of serine 205 as a site of phosphorylation on Pax3 in proliferating but not differentiating primary myoblasts , 2008, Protein science : a publication of the Protein Society.

[2]  H. Farin,et al.  T-box Protein Tbx18 Interacts with the Paired Box Protein Pax3 in the Development of the Paraxial Mesoderm* , 2008, Journal of Biological Chemistry.

[3]  Helen Pickersgill,et al.  Oncogenic BRAF Regulates Melanoma Proliferation through the Lineage Specific Factor MITF , 2008, PloS one.

[4]  Kenneth R Maravilla,et al.  Sensorineural deafness, distinctive facial features, and abnormal cranial bones: A new variant of Waardenburg syndrome? , 2008, American journal of medical genetics. Part A.

[5]  J. Krupiński,et al.  Pax genes in embryogenesis and oncogenesis , 2008, Journal of cellular and molecular medicine.

[6]  J. Epstein,et al.  Pax3 regulation of FGF signaling affects the progression of embryonic progenitor cells into the myogenic program. , 2008, Genes & development.

[7]  J. Plotkin,et al.  Persistent expression of Pax3 in the neural crest causes cleft palate and defective osteogenesis in mice. , 2008, The Journal of clinical investigation.

[8]  D. Fabbro,et al.  Phosphorylation regulates transcriptional activity of PAX3/FKHR and reveals novel therapeutic possibilities. , 2008, Cancer research.

[9]  L. Holland,et al.  The Evolution of Alternative Splicing in the Pax Family: The View from the Basal Chordate Amphioxus , 2008, Journal of Molecular Evolution.

[10]  C. Shea,et al.  PAX3 expression in primary melanomas and nevi , 2008, Modern Pathology.

[11]  S. Ichi,et al.  Key basic helix-loop-helix transcription factor genes Hes1 and Ngn2 are regulated by Pax3 during mouse embryonic development. , 2008, Developmental biology.

[12]  G. Maul,et al.  Regulation of c-met expression by transcription repressor Daxx , 2008, Oncogene.

[13]  J. Epstein,et al.  Cre reporter mouse expressing a nuclear localized fusion of GFP and β‐galactosidase reveals new derivatives of Pax3‐expressing precursors , 2008, Genesis.

[14]  J. Mason,et al.  Pax3 regulates Wnt1 expression via a conserved binding site in the 5' proximal promoter. , 2008, Biochimica et biophysica acta.

[15]  H. Hosoi,et al.  Effects of PAX3-FKHR on malignant phenotypes in alveolar rhabdomyosarcoma. , 2008, Biochemical and biophysical research communications.

[16]  F. Luciani,et al.  Beta-catenin induces immortalization of melanocytes by suppressing p16INK4a expression and cooperates with N-Ras in melanoma development. , 2007, Genes & development.

[17]  W. Cavenee,et al.  PAX3-FOXO1 controls expression of the p57Kip2 cell-cycle regulator through degradation of EGR1 , 2007, Proceedings of the National Academy of Sciences.

[18]  B. Schäfer,et al.  Comparative expression profiling identifies an in vivo target gene signature with TFAP2B as a mediator of the survival function of PAX3/FKHR , 2007, Oncogene.

[19]  C. Bertolotto,et al.  SOX9 is a key player in ultraviolet B-induced melanocyte differentiation and pigmentation , 2007, Proceedings of the National Academy of Sciences.

[20]  C. Parker,et al.  PAX3 and PAX3-FKHR promote rhabdomyosarcoma cell survival through downregulation of PTEN. , 2007, Cancer letters.

[21]  S. Nishikawa,et al.  Generating quiescent stem cells. , 2007, Pigment cell research.

[22]  T. Rando,et al.  Regulation of Pax3 by Proteasomal Degradation of Monoubiquitinated Protein in Skeletal Muscle Progenitors , 2007, Cell.

[23]  R. Alani,et al.  Comprehensive Expression Profiling of Tumor Cell Lines Identifies Molecular Signatures of Melanoma Progression , 2007, PloS one.

[24]  T. McLean,et al.  Pediatric genitourinary tumors , 2007, Current opinion in oncology.

[25]  G. Cossu,et al.  Beta catenin-independent activation of MyoD in presomitic mesoderm requires PKC and depends on Pax3 transcriptional activity. , 2007, Developmental biology.

[26]  R. Marais,et al.  Melanoma biology and new targeted therapy , 2007, Nature.

[27]  Jane Goodall,et al.  Mitf regulation of Dia1 controls melanoma proliferation and invasiveness. , 2006, Genes & development.

[28]  Ya-Li Yao,et al.  Transcriptional repression activity of PAX3 is modulated by competition between corepressor KAP1 and heterochromatin protein 1. , 2006, Biochemical and biophysical research communications.

[29]  S. Baker,et al.  PTEN function in normal and neoplastic growth. , 2006, Cancer letters.

[30]  E. Steingrímsson,et al.  The Microphthalmia-Associated Transcription Factor Mitf Interacts with β-Catenin To Determine Target Gene Expression , 2006, Molecular and Cellular Biology.

[31]  M. Buckingham,et al.  A novel genetic hierarchy functions during hypaxial myogenesis: Pax3 directly activates Myf5 in muscle progenitor cells in the limb. , 2006, Genes & development.

[32]  C. Mayanil,et al.  Regulation of Murine TGFβ2 by Pax3 during Early Embryonic Development* , 2006, Journal of Biological Chemistry.

[33]  R. Hofstra,et al.  RET as a diagnostic and therapeutic target in sporadic and hereditary endocrine tumors. , 2006, Endocrine reviews.

[34]  Y. Uchijima,et al.  Transcriptional activity of Pax3 is co-activated by TAZ. , 2006, Biochemical and biophysical research communications.

[35]  S. Nishikawa,et al.  Molecular characterization of melanocyte stem cells in their niche , 2005, Development.

[36]  D. Underhill,et al.  Pax3 target gene recognition occurs through distinct modes that are differentially affected by disease-associated mutations. , 2005, Pigment cell research.

[37]  P. Natali,et al.  Retinoblastoma protein acts as Pax 8 transcriptional coactivator , 2005, Oncogene.

[38]  R. Sturm,et al.  Co-expression of SOX9 and SOX10 during melanocytic differentiation in vitro. , 2005, Experimental cell research.

[39]  M. Eccles,et al.  Transfection of melanoma cells with antisense PAX3 oligonucleotides additively complements cisplatin-induced cytotoxicity , 2005, Molecular Cancer Therapeutics.

[40]  F. Miller,et al.  Isolation and Characterization of Multipotent Skin‐Derived Precursors from Human Skin , 2005, Stem cells.

[41]  Robert M Hoffman,et al.  Multipotent nestin-positive, keratin-negative hair-follicle bulge stem cells can form neurons. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[42]  J. Epstein,et al.  Pax3 functions at a nodal point in melanocyte stem cell differentiation , 2005, Nature.

[43]  Benjamin R. Arenkiel,et al.  Alveolar rhabdomyosarcomas in conditional Pax3:Fkhr mice: cooperativity of Ink4a/ARF and Trp53 loss of function. , 2004, Genes & development.

[44]  M Grim,et al.  Pluripotent neural crest stem cells in the adult hair follicle , 2004, Developmental dynamics : an official publication of the American Association of Anatomists.

[45]  W. Pavan,et al.  Direct interaction of Sox10 with the promoter of murine Dopachrome Tautomerase (Dct) and synergistic activation of Dct expression with Mitf. , 2004, Pigment cell research.

[46]  A. Radu,et al.  Paired-Type Homeodomain Transcription Factors Are Imported into the Nucleus by Karyopherin 13 , 2004, Molecular and Cellular Biology.

[47]  L. Larue,et al.  Brn-2 Expression Controls Melanoma Proliferation and Is Directly Regulated by β-Catenin , 2004, Molecular and Cellular Biology.

[48]  R. Marais,et al.  The Brn-2 Transcription Factor Links Activated BRAF to Melanoma Proliferation , 2004, Molecular and Cellular Biology.

[49]  Yaping Liu,et al.  Capturing and profiling adult hair follicle stem cells , 2004, Nature Biotechnology.

[50]  E. Fuchs,et al.  Defining the Epithelial Stem Cell Niche in Skin , 2004, Science.

[51]  C. Parker,et al.  Expression of PAX 3 alternatively spliced transcripts and identification of two new isoforms in human tumors of neural crest origin , 2004, International journal of cancer.

[52]  M. Wegner,et al.  Melanocyte‐specific expression of dopachrome tautomerase is dependent on synergistic gene activation by the Sox10 and Mitf transcription factors , 2004, FEBS letters.

[53]  Andreas Russ,et al.  Dorsoventral Patterning of the Mouse Coat by Tbx15 , 2004, PLoS biology.

[54]  E. Dupin,et al.  Multipotentiality of the neural crest. , 2003, Current opinion in genetics & development.

[55]  H. Kayserili,et al.  Homozygous and heterozygous inheritance of PAX3 mutations causes different types of Waardenburg syndrome , 2003, American journal of medical genetics. Part A.

[56]  M. Eccles,et al.  Paired-Box genes are frequently expressed in cancer and often required for cancer cell survival , 2003, Oncogene.

[57]  J. Epstein,et al.  Sox10 and Pax3 physically interact to mediate activation of a conserved c-RET enhancer. , 2003, Human molecular genetics.

[58]  P. S. Klein,et al.  Wnt–frizzled signaling in neural crest formation , 2003, Trends in Neurosciences.

[59]  G. Grosveld,et al.  Pax3-FKHR Knock-In Mice Show Developmental Aberrations but Do Not Develop Tumors , 2002, Molecular and Cellular Biology.

[60]  E. Y. Lee,et al.  Pax-2 interacts with RB and reverses its repression on the promoter of Rig-1, a Robo member. , 2002, Biochemical and biophysical research communications.

[61]  R. Ravazzolo,et al.  Cell‐line specific chromatin acetylation at the Sox10–Pax3 enhancer site modulates the RET proto‐oncogene expression , 2002, FEBS letters.

[62]  Kazuhiro Takahashi,et al.  Microphthalmia‐associated transcription factor interacts with LEF‐1, a mediator of Wnt signaling , 2002, The EMBO journal.

[63]  T. Hibino,et al.  Involvement of transforming growth factor-beta2 in catagen induction during the human hair cycle. , 2002, The Journal of investigative dermatology.

[64]  S. Nishikawa,et al.  Dominant role of the niche in melanocyte stem-cell fate determination , 2002, Nature.

[65]  G. Grosveld,et al.  The EF-hand calcium-binding protein calmyrin inhibits the transcriptional and DNA-binding activity of Pax3. , 2002, Biochimica et biophysica acta.

[66]  M. Loeken,et al.  Rescue of neural tube defects in Pax-3-deficient embryos by p53 loss of function: implications for Pax-3- dependent development and tumorigenesis. , 2002, Genes & development.

[67]  R. Maas,et al.  Msx2 is an immediate downstream effector of Pax3 in the development of the murine cardiac neural crest. , 2002, Development.

[68]  M. Tekin,et al.  Waardenburg syndrome type 3 (Klein–Waardenburg syndrome) segregating with a heterozygous deletion in the paired box domain of PAX3: a simple variant or a true syndrome? , 2001, Clinical genetics.

[69]  W. Pavan,et al.  Analysis of SOX10 function in neural crest-derived melanocyte development: SOX10-dependent transcriptional control of dopachrome tautomerase. , 2001, Developmental biology.

[70]  F. Barr.  Gene fusions involving PAX and FOX family members in alveolar rhabdomyosarcoma , 2001, Oncogene.

[71]  A. Sadikot,et al.  Isolation of multipotent adult stem cells from the dermis of mammalian skin , 2001, Nature Cell Biology.

[72]  V. Pachnis,et al.  Homeodomain proteins Mox1 and Mox2 associate with Pax1 and Pax3 transcription factors , 2001, FEBS letters.

[73]  E. Ziff,et al.  Transcription factors in melanocyte development: distinct roles for Pax-3 and Mitf , 2001, Mechanisms of Development.

[74]  W. Cavenee,et al.  Embryonic expression of the tumor-associated PAX3-FKHR fusion protein interferes with the developmental functions of Pax3. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[75]  R. Dummer,et al.  PAX3 is expressed in human melanomas and contributes to tumor cell survival. , 2001, Cancer research.

[76]  Yann Barrandon,et al.  Morphogenesis and Renewal of Hair Follicles from Adult Multipotent Stem Cells , 2001, Cell.

[77]  P. Pandolfi,et al.  Regulation of Pax3 transcriptional activity by SUMO-1-modified PML , 2001, Oncogene.

[78]  P. Parsons,et al.  Domains of Brn-2 that mediate homodimerization and interaction with general and melanocytic transcription factors. , 2000, European journal of biochemistry.

[79]  J. Epstein,et al.  Pax3 is required for enteric ganglia formation and functions with Sox10 to modulate expression of c-ret. , 2000, The Journal of clinical investigation.

[80]  M. Wegner,et al.  Interaction among SOX10, PAX3 and MITF, three genes altered in Waardenburg syndrome. , 2000, Human molecular genetics.

[81]  S. Conway,et al.  Decreased neural crest stem cell expansion is responsible for the conotruncal heart defects within the splotch (Sp(2H))/Pax3 mouse mutant. , 2000, Cardiovascular research.

[82]  W. Pavan,et al.  Transcription factor hierarchy in Waardenburg syndrome: regulation of MITF expression by SOX10 and PAX3 , 2000, Human Genetics.

[83]  B. Schäfer,et al.  Transcriptional modulation of the anti-apoptotic protein BCL-XL by the paired box transcription factors PAX3 and PAX3/FKHR , 2000, Oncogene.

[84]  Kazuhiro Takahashi,et al.  Induction of Melanocyte-specific Microphthalmia-associated Transcription Factor by Wnt-3a* , 2000, The Journal of Biological Chemistry.

[85]  A. McMahon,et al.  Fate of the mammalian cardiac neural crest. , 2000, Development.

[86]  Yun Cao,et al.  The COOH-terminal Transactivation Domain Plays a Key Role in Regulating the in Vitro and in Vivo Function of Pax3 Homeodomain* , 2000, The Journal of Biological Chemistry.

[87]  M. Shen,et al.  Msx1 antagonizes the myogenic activity of Pax3 in migrating limb muscle precursors. , 1999, Development.

[88]  R. Davis,et al.  Predominant expression of alternative PAX3 and PAX7 forms in myogenic and neural tumor cell lines. , 1999, Cancer research.

[89]  T. Dexter,et al.  Pax3 and Regulation of the Melanocyte-specific Tyrosinase-related Protein-1 Promoter* , 1999, The Journal of Biological Chemistry.

[90]  T. Barber,et al.  PAX3 gene structure, alternative splicing and evolution. , 1999, Gene.

[91]  J. Terzic,et al.  Expression pattern of PAX3 and PAX6 genes during human embryogenesis. , 1999, The International journal of developmental biology.

[92]  G. Grosveld,et al.  The Pax3–FKHR oncoprotein is unresponsive to the Pax3‐associated repressor hDaxx , 1999, The EMBO journal.

[93]  J. Epstein,et al.  Pax3 functions in cell survival and in pax7 regulation. , 1999, Development.

[94]  D. Eberhard,et al.  The partial homeodomain of the transcription factor Pax-5 (BSAP) is an interaction motif for the retinoblastoma and TATA-binding proteins. , 1999, Cancer research.

[95]  C. Goding,et al.  Targeting the Microphthalmia Basic Helix-Loop-Helix–Leucine Zipper Transcription Factor to a Subset of E-Box Elements In Vitro and In Vivo , 1998, Molecular and Cellular Biology.

[96]  Randall T. Moon,et al.  Control of neural crest cell fate by the Wnt signalling pathway , 1998, Nature.

[97]  A. Goriely,et al.  Lune/eye gone, a Pax-like protein, uses a partial paired domain and a homeodomain for DNA recognition. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[98]  P. Scambler,et al.  HIRA, a mammalian homologue of Saccharomyces cerevisiae transcriptional co-repressors, interacts with Pax3 , 1998, Nature Genetics.

[99]  C. R. Goding,et al.  Brachyury-Related Transcription Factor Tbx2 and Repression of the Melanocyte-Specific TRP-1 Promoter , 1998, Molecular and Cellular Biology.

[100]  R. Davis,et al.  Up-regulation of MET but not neural cell adhesion molecule expression by the PAX3-FKHR fusion protein in alveolar rhabdomyosarcoma. , 1998, Cancer research.

[101]  F. Barr,et al.  Structural analysis of PAX3 genomic rearrangements in alveolar rhabdomyosarcoma. , 1998, Cancer genetics and cytogenetics.

[102]  K. Takeda,et al.  Epistatic relationship between Waardenburg Syndrome genes MITF and PAX3 , 1998, Nature Genetics.

[103]  R. Buscà,et al.  Different cis-Acting Elements Are Involved in the Regulation of TRP1 and TRP2 Promoter Activities by Cyclic AMP: Pivotal Role of M Boxes (GTCATGTGCT) and of Microphthalmia , 1998, Molecular and Cellular Biology.

[104]  Giovanni Romeo,et al.  SOX10 mutations in patients with Waardenburg-Hirschsprung disease , 1998, Nature Genetics.

[105]  P. Hamel,et al.  Interaction of the pRB-family proteins with factors containing paired-like homeodomains , 1998, Oncogene.

[106]  M. Wegner,et al.  Sox10, a Novel Transcriptional Modulator in Glial Cells , 1998, The Journal of Neuroscience.

[107]  A. Copp,et al.  Over-expression of the chondroitin sulphate proteoglycan versican is associated with defective neural crest migration in the Pax3 mutant mouse (splotch) , 1997, Mechanisms of Development.

[108]  F. Barr.  Molecular Genetics and Pathogenesis of Rhabdomyosarcoma , 1997, Journal of pediatric hematology/oncology.

[109]  A. Copp,et al.  Development of a lethal congenital heart defect in the splotch (Pax3) mutant mouse. , 1997, Cardiovascular research.

[110]  A. McMahon,et al.  Wnt signalling required for expansion of neural crest and CNS progenitors , 1997, Nature.

[111]  M. Loeken,et al.  Neural Tube Defects in Embryos of Diabetic Mice: Role of the Pax-3 Gene and Apoptosis , 1997, Diabetes.

[112]  G. Boivin,et al.  TGFbeta2 knockout mice have multiple developmental defects that are non-overlapping with other TGFbeta knockout phenotypes. , 1997, Development.

[113]  G. Cossu,et al.  Redefining the Genetic Hierarchies Controlling Skeletal Myogenesis: Pax-3 and Myf-5 Act Upstream of MyoD , 1997, Cell.

[114]  A. Copp,et al.  Pax3 is required for cardiac neural crest migration in the mouse: evidence from the splotch (Sp2H) mutant. , 1997, Development.

[115]  P Gruss,et al.  Pax genes and their roles in cell differentiation and development. , 1996, Current opinion in cell biology.

[116]  B. Schäfer,et al.  Induction of apoptosis in rhabdomyosarcoma cells through down-regulation of PAX proteins. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[117]  P. Vogt,et al.  The hybrid PAX3-FKHR fusion protein of alveolar rhabdomyosarcoma transforms fibroblasts in culture. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[118]  C. Desplan,et al.  Cooperative interactions between paired domain and homeodomain. , 1996, Development.

[119]  J. Epstein,et al.  Pax3 modulates expression of the c-Met receptor during limb muscle development. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[120]  J. Biegel,et al.  Structural characterization of the FKHR gene and its rearrangement in alveolar rhabdomyosarcoma. , 1995, Human molecular genetics.

[121]  S. F. Konieczny,et al.  Transcription factor families: muscling in on the myogenic program , 1995, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[122]  D. Bennett,et al.  The POU domain transcription factor Brn-2: elevated expression in malignant melanoma and regulation of melanocyte-specific gene expression. , 1995, Oncogene.

[123]  P. Gruss,et al.  A transgenic neuroanatomical marker identifies cranial neural crest deficiencies associated with the Pax3 mutant Splotch. , 1995, Developmental biology.

[124]  G. Chalepakis,et al.  Identification of DNA recognition sequences for the Pax3 paired domain. , 1995, Gene.

[125]  J. Kuriyan,et al.  High resolution crystal structure of a paired (Pax) class cooperative homeodomain dimer on DNA , 1995, Cell.

[126]  P. Woloshin,et al.  MSX1 inhibits MyoD expression in fibroblast × 10T½ cell hybrids , 1995, Cell.

[127]  G. Sutherland,et al.  The brn-2 gene regulates the melanocytic phenotype and tumorigenic potential of human melanoma cells. , 1995, Oncogene.

[128]  F. Barr,et al.  Wild type PAX3 protein and the PAX3-FKHR fusion protein of alveolar rhabdomyosarcoma contain potent, structurally distinct transcriptional activation domains. , 1995, Oncogene.

[129]  I. Lerer,et al.  Homozygosity for Waardenburg syndrome. , 1995, American journal of human genetics.

[130]  F. Barr,et al.  The PAX3-FKHR fusion protein created by the t(2;13) translocation in alveolar rhabdomyosarcomas is a more potent transcriptional activator than PAX3 , 1995, Molecular and cellular biology.

[131]  Claude Desplan,et al.  Crystal structure of a paired domain-DNA complex at 2.5 å resolution reveals structural basis for pax developmental mutations , 1995, Cell.

[132]  G. Edelman,et al.  Pax-3 contains domains for transcription activation and transcription inhibition. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[133]  W. Reardon,et al.  The mutational spectrum in Waardenburg syndrome. , 1994, Human molecular genetics.

[134]  J. Wijnholds,et al.  Pax-3-DNA interaction: flexibility in the DNA binding and induction of DNA conformational changes by paired domains. , 1994, Nucleic acids research.

[135]  P. Parsons,et al.  Expression studies of pigmentation and POU-domain genes in human melanoma cells. , 1994, Pigment cell research.

[136]  U. Yavuzer,et al.  Melanocyte-specific gene expression: role of repression and identification of a melanocyte-specific factor, MSF , 1994, Molecular and cellular biology.

[137]  M. Goulding,et al.  Molecular basis of splotch and Waardenburg Pax-3 mutations. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[138]  M. Goulding,et al.  Regulation of Pax-3 expression in the dermomyotome and its role in muscle development. , 1994, Development.

[139]  H. Arnold,et al.  Pax-3 is required for the development of limb muscles: a possible role for the migration of dermomyotomal muscle progenitor cells. , 1994, Development.

[140]  P. Gruss,et al.  Pax genes in development , 1994, Journal of Cell Science.

[141]  H. Hamada,et al.  A CNS-specific POU transcription factor, Brn-2, is required for establishing mammalian neural cell lineages , 1993, Neuron.

[142]  J. Downing,et al.  Fusion of PAX3 to a member of the forkhead family of transcription factors in human alveolar rhabdomyosarcoma. , 1993, Cancer research.

[143]  B. Emanuel,et al.  Fusion of a fork head domain gene to PAX3 in the solid tumour alveolar rhabdomyosarcoma , 1993, Nature Genetics.

[144]  K. Vogan,et al.  The splotch-delayed (Spd) mouse mutant carries a point mutation within the paired box of the Pax-3 gene. , 1993, Genomics.

[145]  M. Goulding,et al.  Signals from the notochord and floor plate regulate the region-specific expression of two Pax genes in the developing spinal cord. , 1993, Development.

[146]  T. Franz.  The Splotch (Sp1H) and Splotch-delayed (Spd) alleles: differential phenotypic effects on neural crest and limb musculature , 1993, Anatomy and Embryology.

[147]  C. Baldwin,et al.  Mutations in the paired domain of the human PAX3 gene cause Klein-Waardenburg syndrome (WS-III) as well as Waardenburg syndrome type I (WS-I). , 1993, American journal of human genetics.

[148]  M. Surani,et al.  The Splotch mutation interferes with muscle development in the limbs , 1993, Anatomy and Embryology.

[149]  J. Biegel,et al.  Rearrangement of the PAX3 paired box gene in the paediatric solid tumour alveolar rhabdomyosarcoma , 1993, Nature Genetics.

[150]  K. Vogan,et al.  A mutation within intron 3 of the Pax-3 gene produces aberrantly spliced mRNA transcripts in the splotch (Sp) mouse mutant. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[151]  T. Friedman,et al.  A frameshift mutation in the HuP2 paired domain of the probable human homolog of murine Pax-3 is responsible for Waardenburg syndrome type 1 in an Indonesian family. , 1992, Human molecular genetics.

[152]  K. Arnos,et al.  Waardenburg syndrome (WS) type I is caused by defects at multiple loci, one of which is near ALPP on chromosome 2: first report of the WS consortium. , 1992, American journal of human genetics.

[153]  C. Baldwin,et al.  An exonic mutation in the HuP2 paired domain gene causes Waardenburg's syndrome , 1992, Nature.

[154]  R. Balling,et al.  Waardenburg's syndrome patients have mutations in the human homologue of the Pax-3 paired box gene , 1992, Nature.

[155]  P. Gros,et al.  splotch (Sp2H ), a mutation affecting development of the mouse neural tube, shows a deletion within the paired homeodomain of Pax-3 , 1991, Cell.

[156]  M. Goulding,et al.  Pax‐3, a novel murine DNA binding protein expressed during early neurogenesis. , 1991, The EMBO journal.

[157]  D. Malo,et al.  Molecular characterization of a deletion encompassing the splotch mutation on mouse chromosome 1. , 1991, Genomics.

[158]  C. Desplan,et al.  The paired box encodes a second DNA-binding domain in the paired homeo domain protein. , 1991, Genes & development.

[159]  A. Strasser,et al.  Novel murine homeo box gene on chromosome 1 expressed in specific hematopoietic lineages and during embryogenesis. , 1991, Genes & development.

[160]  T. Friedman,et al.  Mouse and hamster mutants as models for Waardenburg syndromes in humans. , 1990, Journal of medical genetics.

[161]  D. Trasler,et al.  Delayed neural crest cell emigration from Sp and Spd mouse neural tube explants. , 1990, Teratology.

[162]  A. Read,et al.  Assignment of the locus for Waardenburg syndrome type I to human chromosome 2q37 and possible homology to the Splotch mouse. , 1990, American journal of human genetics.

[163]  N. Niikawa,et al.  Waardenburg syndrome type I in a child with de novo inversion (2)(q35q37.3). , 1989, American journal of medical genetics.

[164]  D. Trasler,et al.  Spinal ganglia reduction in the splotch-delayed mouse neural tube defect mutant. , 1989, Teratology.

[165]  J. Delleman,et al.  Heterogeneity in Waardenburg syndrome. , 1977, American journal of human genetics.

[166]  M. Dickie.  NEW SPLOTCH ALLELES IN THE MOUSE. , 1964, The Journal of heredity.

[167]  R. Auerbach.  Analysis of the developmental effects of a lethal mutation in the house mouse , 1954 .

[168]  M. Dickie,et al.  Linkage of loop-tail, leaden, splotch and fuzzy in the mouse , 1954, Heredity.

[169]  Waardenburg Pj.  A new syndrome combining developmental anomalies of the eyelids, eyebrows and nose root with pigmentary defects of the iris and head hair and with congenital deafness. , 1951 .

[170]  B. Ruggeri,et al.  PAX genes: roles in development, pathophysiology, and cancer. , 2007, Biochemical pharmacology.

[171]  J. Sánchez de Toledo Codina,et al.  Molecular biology of rhabdomyosarcoma , 2007, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

[172]  C. Mayanil,et al.  Regulation of murine TGFbeta2 by Pax3 during early embryonic development. , 2006, The Journal of biological chemistry.

[173]  Adrian A Canutescu,et al.  Formation of MacroH2A-containing senescence-associated heterochromatin foci and senescence driven by ASF1a and HIRA. , 2005, Developmental cell.

[174]  T. Franz.  Persistent truncus arteriosus in the Splotch mutant mouse , 2004, Anatomy and Embryology.

[175]  W. Pavan,et al.  SOX10 mutation disrupts neural crest development in Dom Hirschsprung mouse model , 1998, Nature Genetics.

[176]  P. Woloshin,et al.  MSX1 inhibits myoD expression in fibroblast x 10T1/2 cell hybrids. , 1995, Cell.

[177]  F. Barr,et al.  The PAX 3-FKHR Fusion Protein Created by the t ( 2 ; 13 ) Translocation in Alveolar Rhabdomyosarcomas Is a More Potent Transcriptional Activator than PAX 3 , 1995 .

[178]  M. Tassabehji,et al.  Mutations in the PAX3 gene causing Waardenburg syndrome type 1 and type 2 , 1993, Nature Genetics.

[179]  B. Cowan,et al.  Pediatric genitourinary tumors. , 1992, Current opinion in oncology.

[180]  T. Franz.  Defective ensheathment of motoric nerves in the Splotch mutant mouse. , 1990, Acta anatomica.

[181]  F. Meire,et al.  Waardenburg syndrome , 2020, Definitions.

[182]  P. J. Waardenburg.  A new syndrome combining developmental anomalies of the eyelids, eyebrows and nose root with pigmentary defects of the iris and head hair and with congenital deafness. , 1951, American journal of human genetics.